These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 499306)

  • 1. Absorption of quinidine from an enteric-coated preparation.
    Fremstad D; Nilsen OG; Amlie J; Storstein L; Olsson B; Jacobsen S
    Eur J Clin Pharmacol; 1979 Sep; 16(2):107-12. PubMed ID: 499306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enteric coated quinidine compared to sustained release preparations during repeated administration.
    Bakke OM; Aanderud L; Aslaksen A
    Acta Med Scand; 1980; 207(3):183-7. PubMed ID: 7368984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Understanding the in vivo performance of enteric coated tablets using an in vitro-in silico-in vivo approach: case example diclofenac.
    Kambayashi A; Blume H; Dressman J
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1337-47. PubMed ID: 24056057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bioavailability of quinidine in slow-release form. A comparison between two preparations containing quinidine bisulphate as the active constituent.
    Regårdh CG; Johnsson G; Lundborg P; Perrson BA
    Arzneimittelforschung; 1977; 27(9):1716-8. PubMed ID: 21671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Absolute bioavailability of quinidine in two sustained release preparations.
    Amlie JP; Storstein L; Olsson B; Fremstad D; Jacobsen S
    Eur J Clin Pharmacol; 1979 Aug; 16(1):45-8. PubMed ID: 499299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of food on the absorption of acetylsalicylic acid from enteric-coated dosage forms.
    Bogentoft C; Carlsson I; Ekenved G; Magnusson A
    Eur J Clin Pharmacol; 1978 Dec; 14(5):351-5. PubMed ID: 32046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of food on the absorption and pharmacokinetics of prednisolone from enteric-coated tablets.
    Al-Habet SM; Rogers HJ
    Eur J Clin Pharmacol; 1989; 37(4):423-6. PubMed ID: 2598978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bioavailability of 11 quinidine formulations adn pharmacokinetic variation in humans.
    McGilveray IJ; Midha KK; Rowe M; Beaudoin N; Charette C
    J Pharm Sci; 1981 May; 70(5):524-9. PubMed ID: 7241357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Absolute quinidine bioavailability.
    Ueda CT; Williamson BJ; Dzindzio BS
    Clin Pharmacol Ther; 1976 Sep; 20(3):260-5. PubMed ID: 954347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The influence of food on the absorption of diclofenac after single and multiple oral doses.
    Willis JV; Kendall MJ; Jack DB
    Eur J Clin Pharmacol; 1981 Jan; 19(1):33-7. PubMed ID: 7461021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of food on the pharmacokinetics of nifedipine in two slow release formulations: pronounced lag-time after a high fat breakfast.
    Schug BS; Brendel E; Chantraine E; Wolf D; Martin W; Schall R; Blume HH
    Br J Clin Pharmacol; 2002 Jun; 53(6):582-8. PubMed ID: 12047482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the absorption from some commercial enteric-release theophylline products.
    Upton RA; Powell JR; Guentert TW; Thiercelin JF; Sansom L; Coates PE; Riegelman S
    J Pharmacokinet Biopharm; 1980 Apr; 8(2):151-64. PubMed ID: 7431220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of food and tablet formulation on plasma prednisolone levels following administration of enteric-coated tablets.
    Lee DA; Taylor GM; Walker JG; James VH
    Br J Clin Pharmacol; 1979 May; 7(5):523-8. PubMed ID: 475947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigation of the relationship between in vitro and in vivo release behaviors of acamprosate from enteric-coated tablets.
    Rhee YS; Park S; Lee TW; Park CW; Nam TY; Oh TO; Jeon JW; Lee DS; Park ES
    Arch Pharm Res; 2008 Jun; 31(6):798-804. PubMed ID: 18563364
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bioavailability of three commercial sustained-release tablets of quinidine in maintenance therapy.
    Huynh-Ngoc T; Chabot M; Sirois G
    J Pharm Sci; 1978 Oct; 67(10):1456-9. PubMed ID: 702302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of decrease in both postprandial blood glucose (PBG) and fasting blood glucose (FBG) levels in normal beagle dogs with nateglinide enteric coated granules and immediate release tablets.
    Makino C; Ninomiya N; Sakai H; Orita H; Okano A; Yabuki A
    Chem Pharm Bull (Tokyo); 2006 Apr; 54(4):409-14. PubMed ID: 16595936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bioavailability of a commercial sustained-release quinidine tablet compared to oral quinidine solution.
    Sawyer WT; Pulliam CC; Mattocks A; Foster J; Hadzija BW; Rosenthal HM
    Biopharm Drug Dispos; 1982; 3(4):301-10. PubMed ID: 7159686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serious bioavailability problems with a generic prolonged-release quinidine gluconate product.
    Meyer MC; Straughn AB; Lieberman P; Jacob J
    J Clin Pharmacol; 1982; 22(2-3):131-4. PubMed ID: 7068936
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Absorption of acetylsalicylic acid from enteric-coated tablets in relation to gastric emptying and in-vivo disintegration.
    Bogentoft C; Alpsten M; Ekenved G
    J Pharm Pharmacol; 1984 May; 36(5):350-1. PubMed ID: 6145780
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enteric-coated tablets improve oral bioavailability of DX-9065, a novel anticoagulant.
    Fujii Y; Kanamaru T; Kikuchi H; Yamashita S; Sakuma S
    Eur J Pharm Sci; 2011 Mar; 42(4):392-9. PubMed ID: 21238588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.